MoonLake Immunotherapeuti... (MLTX)

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

undefined

undefined%

At close: undefined

51.34

-0.10%

After-hours Dec 13, 2024, 04:00 PM EST

Company Description

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies.

It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation.

The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis.

MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics

Country	CH
IPO Date	Oct 20, 2020
Industry	Biotechnology
Sector	Healthcare
Employees	50
CEO	Dr. Jorge Santos da Silva

Contact Details

Address: Dorfstrasse 29 Zug, CH
Website	https://www.moonlaketx.com

Stock Details

Ticker Symbol	MLTX
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001821586
CUSIP Number	61559X104
ISIN Number	KY61559X1045
Employer ID	00-0000000
SIC Code	2834

Key Executives

Name	Position
Dr. Jorge Santos da Silva	Co-Founder, Chief Executive Officer & Director
Matthias Bodenstedt	Chief Financial Officer
Carla Bretes	Director Investor Relations & Business Development
Dr. Kristian Reich	Co-Founder & Chief Scientific Officer
Joana Cortez	Senior Director Legal & Compliance
Luciana Marques	Director of HR, People & Culture
Nicolas Mosimann	General Counsel
Nuala Brennan	Chief Clinical Development Officer
Oliver Daltrop Ph.D.	Chief Operations Officer
Tino Anthamatten	Vice President of Marketing, Market Access & Pricing

Latest SEC Filings

Date	Type	Title
Nov 12, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial own...
Nov 07, 2024	10-Q	Quarterly Report
Nov 07, 2024	8-K	Current Report
Oct 08, 2024	4	Filing
Oct 08, 2024	SC 13D/A	[Amend] Filing
Oct 08, 2024	4	Filing
Sep 11, 2024	8-K	Current Report
Aug 07, 2024	10-Q	Quarterly Report
Aug 07, 2024	8-K	Current Report
Jun 10, 2024	4	Filing

View All SEC Filings